Login to Your Account



Day after Pfizer merger blow-up, Allergan moves on, inking $3.3B pact with Heptares

By Nuala Moran
Staff Writer

Thursday, April 7, 2016

LONDON – Allergan plc has bounced back from the severing of its $160 billion betrothal to Pfizer Inc., to announce a $3.3 billion collaboration in Alzheimer's disease and other neurological disorders, with GPCR specialist Heptares Therapeutics.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription